These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 22441534)

  • 1. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
    Kim SR; El-Shamy A; Imoto S; Kim KI; Ide YH; Deng L; Shoji I; Tanaka Y; Hasegawa Y; Ota M; Hotta H
    J Gastroenterol; 2012 Oct; 47(10):1143-51. PubMed ID: 22441534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load.
    Kim SR; El-Shamy A; Imoto S; Kim KI; Sugimoto K; Kim SK; Tanaka Y; Hatae T; Hasegawa Y; Fujinami A; Ohta M; Hotta H; Kudo M
    Dig Dis; 2013; 31(5-6):426-33. PubMed ID: 24281016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.
    El-Shamy A; Nagano-Fujii M; Sasase N; Imoto S; Kim SR; Hotta H
    Hepatology; 2008 Jul; 48(1):38-47. PubMed ID: 18537193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype.
    Guo X; Zhao Z; Xie J; Cai Q; Zhang X; Peng L; Gao Z
    Virol J; 2012 Jun; 9():123. PubMed ID: 22713131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
    Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Honda M; Sugiyama M; Matsuura K; Sugauchi F; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Sakai A; Kaneko S; Ito K; Masaki N; Tokunaga K; Izumi N; Mizokami M
    J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
    Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Kim SR; Ide YH; Sasase N; Imoto S; Deng L; Shoji I; Hotta H
    Intervirology; 2012; 55(1):1-11. PubMed ID: 21293098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
    PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
    Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
    Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.
    Maekawa S; Sakamoto M; Miura M; Kadokura M; Sueki R; Komase K; Shindo H; Komatsu N; Shindo K; Kanayama A; Ohmori T; Amemiya F; Takano S; Yamaguchi T; Nakayama Y; Kitamura T; Inoue T; Okada S; Enomoto N
    Hepatology; 2012 Nov; 56(5):1611-21. PubMed ID: 22577043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
    Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
    Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
    Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
    Tamai H; Mori Y; Shingaki N; Kawashima A; Tsukuda H; Higashi K; Moribata K; Kawaguchi M; Ueda K; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
    Antivir Ther; 2014; 19(1):107-15. PubMed ID: 24162072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(6):1059-67. PubMed ID: 22898703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
    Hepatology; 2010 Aug; 52(2):421-9. PubMed ID: 20648473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
    Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.